PortalPublikationenEvidence-based (S3) guideline for the treatment of psoriasis...

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".

Standard

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". / Nast, Alexander; Augustin, Matthias; Boehncke, Wolf-Henning; Klaus, Joachim; Mrowietz, Ulrich; Ockenfels, Hans-Michael; Philipp, Sandra; Reich, Kristian; Rosenbach, Thomas; Schlaeger, Martin; Sebastian, Michael; Sterry, Wolfram; Streit, Volker; Weisenseel, Peter; Rzany, Berthold.

in: J DTSCH DERMATOL GES, Jahrgang 8, Nr. 1, 1, 2010, S. 65-66.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Nast, A, Augustin, M, Boehncke, W-H, Klaus, J, Mrowietz, U, Ockenfels, H-M, Philipp, S, Reich, K, Rosenbach, T, Schlaeger, M, Sebastian, M, Sterry, W, Streit, V, Weisenseel, P & Rzany, B 2010, 'Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".', J DTSCH DERMATOL GES, Jg. 8, Nr. 1, 1, S. 65-66. <http://www.ncbi.nlm.nih.gov/pubmed/20096063?dopt=Citation>

APA

Nast, A., Augustin, M., Boehncke, W-H., Klaus, J., Mrowietz, U., Ockenfels, H-M., Philipp, S., Reich, K., Rosenbach, T., Schlaeger, M., Sebastian, M., Sterry, W., Streit, V., Weisenseel, P., & Rzany, B. (2010). Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". J DTSCH DERMATOL GES, 8(1), 65-66. [1]. http://www.ncbi.nlm.nih.gov/pubmed/20096063?dopt=Citation

Vancouver

Nast A, Augustin M, Boehncke W-H, Klaus J, Mrowietz U, Ockenfels H-M et al. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". J DTSCH DERMATOL GES. 2010;8(1):65-66. 1.

Bibtex

@article{83933653560341218ba883a93b2c0f14,
title = "Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: {"}Therapeutic options{"} and {"}Efalizumab{"}.",
abstract = "In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.",
author = "Alexander Nast and Matthias Augustin and Wolf-Henning Boehncke and Joachim Klaus and Ulrich Mrowietz and Hans-Michael Ockenfels and Sandra Philipp and Kristian Reich and Thomas Rosenbach and Martin Schlaeger and Michael Sebastian and Wolfram Sterry and Volker Streit and Peter Weisenseel and Berthold Rzany",
year = "2010",
language = "Deutsch",
volume = "8",
pages = "65--66",
journal = "J DTSCH DERMATOL GES",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".

AU - Nast, Alexander

AU - Augustin, Matthias

AU - Boehncke, Wolf-Henning

AU - Klaus, Joachim

AU - Mrowietz, Ulrich

AU - Ockenfels, Hans-Michael

AU - Philipp, Sandra

AU - Reich, Kristian

AU - Rosenbach, Thomas

AU - Schlaeger, Martin

AU - Sebastian, Michael

AU - Sterry, Wolfram

AU - Streit, Volker

AU - Weisenseel, Peter

AU - Rzany, Berthold

PY - 2010

Y1 - 2010

N2 - In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.

AB - In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.

M3 - SCORING: Zeitschriftenaufsatz

VL - 8

SP - 65

EP - 66

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 1

M1 - 1

ER -